文献速递类风湿关节炎

BMI对类风湿关节炎JAK抑制剂疗效的影响:随机对照试验个体患者数据Meta分析

Impact of BMI on response to Janus kinase inhibitors in rheumatoid arthritis: an individual patient data meta-analysis of randomised controlled trials.
PubMed 文献 · Lancet Rheumatol · 2026-08-03

结果显示较高BMI与JAK抑制剂疗效降低相关,肥胖为效应修饰因素,提示应将体重管理纳入常规诊疗。

要点

  • 较高BMI与JAK抑制剂治疗类风湿关节炎的疗效降低相关。
  • 肥胖(尤其3级肥胖)患者ACR20应答和DAS28-CRP改善均更差。
  • 安慰剂组未见相应BMI梯度,支持肥胖为效应修饰因素。

核心结论

  • 较高BMI与JAK抑制剂疗效降低及治疗获益减少相关,肥胖为效应修饰因素。

研究设计与样本

  • 试验涉及托法替布、巴瑞替尼、乌帕替尼和菲戈替尼,含安慰剂或阳性对照,个体数据通过Vivli平台获取。

主要发现

  • 较高BMI在所有终点均与JAK抑制剂疗效降低相关。
  • 安慰剂组未观察到相应的BMI梯度。
  • 研究间异质性低至中等(I2=0-40%),个体研究总体偏倚风险低。

关键数值与推荐

  • BMI分类:健康体重、超重(25至<30 kg/m2)、1级肥胖(30至<35 kg/m2)、2级肥胖(35至<40 kg/m2)、3级肥胖(≥40 kg/m2)。
  • 主要结局为试验定义的主要疗效时间点的ACR20应答和DAS28-CRP。

临床怎么用

  • 对类风湿关节炎患者使用JAK抑制剂时应考虑BMI对疗效的潜在影响。
  • 支持将体重管理整合到类风湿关节炎常规诊疗中。
  • 未来临床试验应改善BMI代表性和分层分析。

局限性

  • 菲戈替尼试验因变量不足被排除。
  • 研究设计或实施未纳入有亲身经历者参与。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity is common in patients with rheumatoid arthritis and is associated with poorer disease outcomes. We aimed to evaluate the association between BMI and clinical response to Janus kinase (JAK) inhibitors in patients with rheumatoid arthritis using individual patient data from the JAK inhibitor randomised controlled trial programmes. METHODS: In this individual patient data meta-analysis, ClinicalTrials.gov was searched from database inception to Jan 13, 2025, for phase 3, randomised controlled trials of tofacitinib, baricitinib, upadacitinib, and filgotinib in adult patients with rheumatoid arthritis, with a placebo or active comparator. Individual patient data were obtained via the Vivli data-sharing platform. The primary outcomes were a 20% improvement based on American College of Rheumatology (ACR) core set variables (ACR20) and Disease Activity Score based on the evaluation of 28 joints and C-reactive protein (DAS28-CRP), at the trial-defined primary efficacy timepoint. BMI was analysed as a continuous and categorical variable using one-stage mixed-effects models, and validated using a two-stage individual patient data meta-analysis. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool. There was no involvement of people with lived experience in the study design or conduct. This study is registered with PROSPERO (CRD420251180005). FINDINGS: 16 trials contributed individual patient data from 11 883 participants (9588 [80·7%] women and 2293 [19·3%] men, and two with missing sex data). Mean age was 52·9 years (SD 12·3). 8493 (71·5%) of 11 883 participants were White, 2142 (18·0%) were Asian, 439 (3·7%) were Black, and 809 (6·8%) were of other ethnicity. 7765 received tofacitinib, upadacitinib, or baricitinib. Filgotinib trials were excluded due to insufficient variables. Median BMI was 26·8 kg/m2 (IQR 23·2-31·3) and 3676 (30·9%) patients had class 1-3 obesity. Higher BMI was associated with reduced JAK inhibitor efficacy across all endpoints. Compared with patients with healthy weight, adjusted relative risk for ACR20 response was 0·94 (95% CI 0·91-0·98) for patients with overweight (25 to <30 kg/m2), 0·92 (0·89-0·96) for class 1 obesity (30 to <35 kg/m2), 0·88 (0·81-0·96) for class 2 obesity (35 to <40 kg/m2), and 0·78 (0·71-0·85) for class 3 obesity (≥40 kg/m2). For DAS28-CRP, adjusted mean differences compared with healthy weight were 0·14 (95% CI 0·06-0·22) for overweight, 0·21 (0·12-0·31) for class 1 obesity, 0·30 (0·16-0·44) for class 2 obesity, and 0·54 (0·37-0·70) for class 3 obesity. No corresponding BMI gradient was observed in the placebo group. Between-study heterogeneity was low to moderate (I2=0-40%). Overall risk of bias in individual studies was low. INTERPRETATION: Higher BMI was associated with poorer response and a reduced treatment benefit with JAK inhibitors, with obesity acting as an effect modifier. These findings support integration of weight management into routine care for rheumatoid arthritis and improved BMI representation in future trials. FUNDING: None.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Bechman K, Russell MD, Biddle K, et al. Impact of BMI on response to Janus kinase inhibitors in rheumatoid arthritis: an individual patient data meta-analysis of randomised controlled trials. Lancet Rheumatol. 2026. PMID: 42546722. doi:10.1016/S2665-9913(26)00151-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。